Middle East and Africa Heparin Market, By Product Type (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH)), Mode of Administration (Oral, Parenteral), Source (Bovine, Porcine), Ingredients (Sodium, Calcium, Others), Availability (Raw, Processed), Treatment (Deep Vein Thrombosis, Pulmonary Embolism, Arterial Thromboembolism, Others), Application (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Diagnostic Tests, Others), Therapeutics (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Strength (10 Unit, 100 Unit, 1000 Unit, 5000 Unit, 10000 Unit, 25000 Unit, Others), Type (Generics, Brands), Container (Bottles, Bags, Vials, Others), Packaging (Glass, Plastic), End-User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Drug Store, Online Pharmacy, Others) - Industry Trends and Forecast to 2030.
Middle East and Africa Heparin Market Analysis and Size
As countries in the Middle East and Africa continue to invest in healthcare infrastructure and services, there is a growing ability to diagnose and treat various medical conditions, including cardiovascular diseases and thrombotic disorders, for which heparin is commonly used. The region is witnessing an aging population, which is more susceptible to various medical conditions that require anticoagulant therapy. Heparin is widely used in the management of thromboembolic diseases, which become more common with age.
Data Bridge Market Research analyses that the Middle East and Africa heparin market which was USD 153.20 million in 2022, is expected to reach USD 285.67 million by 2030, and is expected to undergo a CAGR of 8.1% during the forecast period. This indicates the market value. “Unfractionated Heparin” dominates the product type segment of the Middle East and Africa heparin market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Middle East and Africa Heparin Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH)), Mode of Administration (Oral, Parenteral), Source (Bovine, Porcine), Ingredients (Sodium, Calcium, Others), Availability (Raw, Processed), Treatment (Deep Vein Thrombosis, Pulmonary Embolism, Arterial Thromboembolism, Others), Application (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Diagnostic Tests, Others), Therapeutics (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Strength (10 Unit, 100 Unit, 1000 Unit, 5000 Unit, 10000 Unit, 25000 Unit, Others), Type (Generics, Brands), Container (Bottles, Bags, Vials, Others), Packaging (Glass, Plastic), End--User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Drug Store, Online Pharmacy, Others)
|
|
Countries Covered
|
Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Sanofi (France), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland) , Mylan N.V.(U.S.), Aspen Holdings (South Africa), Fresenius Kabi AG (Germany), Hebei Changshan Biochemical Pharmaceutical Co. Ltd.(China), Hikma Pharmaceuticals PLC (U.K.), LEO Pharma A/S (Denmark)
|
|
Market Opportunities
|
|
Market Definition
The heparin market is the global pharmaceutical and healthcare sector that involves the production, distribution, and use of heparin, which is an anticoagulant medication. Heparin is a naturally occurring substance found in the body and is also produced synthetically for medical purposes. It is commonly used to prevent or treat conditions characterized by abnormal blood clotting, such as deep vein thrombosis (DVT), pulmonary embolism, and certain cardiovascular procedures such as open-heart surgery.
Middle East and Africa Heparin Market Dynamics
Drivers
- Increasing Healthcare Expenditure
As countries in the Middle East and Africa continue to invest in healthcare infrastructure and services, there is a growing ability to diagnose and treat various medical conditions, including cardiovascular diseases and thrombotic disorders, for which heparin is commonly used
- Rising Incidence of Chronic Diseases
The prevalence of chronic diseases such as heart diseases, diabetes, and cancer is increasing in the Middle East and Africa. Heparin is often used as an anticoagulant in the treatment of patients with these conditions
Opportunities
- Rising Research and Development
Opportunities exist for pharmaceutical companies and research institutions in the MEA region to conduct research on heparin and its potential applications. This can lead to the development of innovative formulations and delivery methods
Restraint/Challenge
- Regulatory Hurdles
Meeting regulatory requirements for the production, import, and distribution of pharmaceutical products, including heparin, can be complex in some MEA countries. Differing regulatory standards and requirements across countries can present challenges for manufacturers and distributors seeking to enter multiple markets
This Middle East and Africa heparin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa heparin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Development
- In August 2022, FDA approved Momenta Pharmaceuticals, Inc.'s M-Enoxaparin product. Together with Sandoz, the generics arm of Novartis AG, Momenta is creating M-Enoxaparin, a technology-enhanced generic version of lovenox
Middle East and Africa Heparin Market Scope
The Middle East and Africa heparin market is segmented on the basis of product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end-user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Unfractionated Heparin
- Low Molecular Weight Heparin (LMWH)
- Ultra-Low Molecular Weight Heparin (ULMWH)
Mode of Administration
- Oral
- Parenteral
Source
- Bovine
- Porcine
Ingredients
- Sodium
- Calcium
- Others
Availability
- Raw
- Processed
Treatment
- Deep Vein Thrombosis
- Pulmonary Embolism
- Arterial Thromboembolism
- Others
Application
- Pre-Surgical Procedures
- Post-Surgical Procedures
- Kidney Dialysis
- Diagnostic Tests
- Others
Therapeutics
- Cardiovascular
- Respiratory
- Oncology
- Nephrology
- CNS
- Others
Strength
- 10 Unit
- 100 Unit
- 1000 Unit
- 5000 Unit
- 10000 Unit
- 25000 Unit
- Others
Type
- Generics
- Brands
Container
- Bottles
- Bags
- Vials
- Others
Packaging
- Glass
- Plastic
End User
- Hospitals
- Clinics
- Homecare
- Ambulatory Surgical Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy and Drug Store
- Online Pharmacy
- Others
Middle East and Africa Heparin Market Regional Analysis/Insights
Middle East and Africa heparin market is analyzed, and market size insights and trends are provided by product type, mode of administration, source, ingredients, availability, treatment, application, therapeutics, strength, type, container, packaging, end-user, and distribution channel as referenced above.
The countries covered in the Middle East and Africa heparin market report are Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
Saudi Arabia dominates the heparin market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to rising healthcare expenditure will further propel the market's growth rate in this region. In addition, favorable health remuneration policies, rise in chronic wounds, and a growing elderly population will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The heparin market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for heparin market impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the heparin market. The data is available for historic period 2015 to 2020
Competitive Landscape and Heparin Market Share Analysis
The heparin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to heparin market.
Some of the major players operating in the heparin market are:
- Sanofi (France)
- Pfizer Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V.(U.S.)
- Aspen Holdings (South Africa)
- Fresenius Kabi AG (Germany)
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd.(China)
- Hikma Pharmaceuticals PLC (U.K.)
- LEO Pharma A/S (Denmark)
SKU-